Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy

Journal of Infection

Volumn 51, Issue 3, 2005, Pages 195-200

  Macias, Juan ^a   Palomares, José C ^a   Mira, José A ^a   Torres, María J ^b   García García, José A ^a   Rodríquez, José M ^b   Vergera, Salvador ^a   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Antiretroviral therapy; Resistance mutations; Transient rebound of HIV viremia

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE DERIVATIVE; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRANSCRIPTASE; VIRUS RNA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HEALTH CARE AVAILABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NUCLEIC ACID AMPLIFICATION; PATIENT COMPLIANCE; PATIENT SELECTION; PROMOTER REGION; RNA EXTRACTION; SEQUENCE ANALYSIS; TREATMENT FAILURE; VIREMIA; VIROLOGY; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 27644580383     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2004.11.010     Document Type: Article

References (17)

1. D.V. Havlir R. Bassett D. Levitan et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy JAMA 286 2001 171-9
2. J.A. Mira J. Macías C. Nogales J. Fernández-Rivera J.A. García-García A. Ramos J.A. Pineda Transient rebounds of low-level viremia among HIV-infected patients under HAART are not associated with virological or immunological failure Antivir Ther 7 2002 251-6
3. J. Martínez-Picado M.P. DePasquale N. Kartsonis et al. Antiretroviral resistance during successful therapy of HIV type 1 infection Proc Natl Acad Sci USA 97 2000 10948-53
4. J.W. Cohen Stuart A.M. Wensing C. Kovacs et al. Transient relapses (Blips) of plasma HIV RNA levels during HAART are associated with drug resistance JAIDS 28 2001 105-13
5. P.A. Sklar D.J. Ward R.K. Baker et al. Prevalence and clinical correlates of HIV viremia (blips) in patients with previous suppression below the limits of quantification AIDS 16 2002 2035-41
6. P.J. Easterbrook N. Ives A. Waters J. Mullen S. O'Shea B. Peters B.G. Gazzard The natural history and clinical significance of intermittent viremia in patients with initial viral suppression to <400 copies/ml AIDS 16 2002 1512-27
7. G. Greub A. Cozzi-Lepri B. Ledergerber et al. Intermittent and sustained low-level HIV viral rebound inpatients receiving potent antiretroviral therapy AIDS 16 2002 1967-9
8. M.R. Furtado D.S. Callaway J.P. Phair et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy N Engl J Med 340 1999 1614-22
9. M.E. Sharkey I. Teo T. Greenough et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy Nat Med 6 2000 76-81
10. G. Dornadula G. Nunnari M. Vanella et al. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups J Infect Dis 183 2001 1682-7
11. M. Hermankova S.C. Ray C. Ruff et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy JAMA 286 2001 196-207
12. M. Di Mascio M. Markowitz M. Louie et al. Viral blip dynamics during highly active antiretroviral therapy J Virol 77 2003 12165-72
13. X. Wei C. Liang M. Gotte M.A. Wainberg The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses AIDS 16 2002 2391-98
14. R.H. Haubrich C.A. Kemper N.S. Hellmann et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: A prospective cohort analysis AIDS 16 2002 F33-F40
15. H. Liu C.E. Golin L.G. Miller R.D. Hays C.K. Beck S. Sanandaji J. Christian T. Maldonado D. Duran A.H. Kaplan N.S. Wenger A comparison study of multiple measures of adherence to HIV protease inhibitors Ann Intern Med 134 2001 1004-6
16. D.R. Bangsberg F.M. Hecht E.D. Charlebois A.R. Zolopa M. Holodniy L. Sheiner J.D. Bamberger M.A. Chesney A. Moss Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population AIDS 14 2000 357-66
17. A.L. Gifford J.E. Bormann M.J. Shively B.C. Wright D.D. Richman S.A. Bozzette Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens J Acquir Immune Defic Syndr 23 2000 386-95